Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the medical expenditure panel survey

Research in Social and Administrative Pharmacy

Volumn 9, Issue 3, 2013, Pages 263-275

  Wang, Chi Chuan ^a   Farley, Joel F ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Antipsychotic; Medical Expenditure Panel Survey; Mental health; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGICAL MODEL; UNITED STATES;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DATA COLLECTION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MODELS, PSYCHOLOGICAL; UNITED STATES;

EID: 84877812909     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2009.07.001     Document Type: Article

References (51)

1. Zuvekas S.H. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff (Millwood) 2005, 24(1):195-205.
2. Kessler R.C., Demler O., Frank R.G., et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005, 352(24):2515-2523.
3. Narrow W.E., Rae D.S., Robins L.N., Regier D.A. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002, 59(2):115-123.
4. Millar H. Management of physical health in schizophrenia: a stepping stone to treatment success. Eur Neuropsychopharmacol 2008, 18(Suppl 2):S121-S128.
5. Skodol A.E. Longitudinal course and outcome of personality disorders. Psychiatr Clin North Am 2008, 31(3):495-503.
6. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry 2008, 69(Suppl 3):38-43.
7. Cotter V.T. The burden of dementia. Am J Manag Care 2007, 13(Suppl 8):S193-S197.
8. Ostacher M.J., Nierenberg A.A., Iosifescu D.V., et al. Correlates of subjective and objective burden among caregivers of patients with bipolar disorder. Acta Psychiatr Scand 2008, 118(1):49-56.
9. Glick I.D., Murray S.R., Vasudevan P., Marder S.R., Hu R.J. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001, 35(3):187-191.
10. Katzung B.G. Basic & Clinical Pharmacology 2007, Lange Medical Books/McGraw-Hill. Medical Publishing Division, New York. 10th ed.
11. U.S. Food and Drug Administration. Available at: . Accessed 11.08.08. http://www.fda.gov/cder/drug/infopage/antipsychotics/default.htm.
12. Cohen L.J. Looking beyond the formulary budget in cost-benefit analysis. Am J Manag Care 1997, 3(Suppl):S11-S17.
13. Daumit G.L., Crum R.M., Guallar E., et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003, 60(2):121-128.
14. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ 2005, 24(1):1-31.
15. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 321(7273):1371-1376.
16. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001, 52:503-517.
17. Stahl S. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers 2002, University of Cambridge, Cambridge, UK.
18. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci 2000, 25(2):137-153.
19. Martin B.C., Miller L.S., Kotzan J.A. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr Res 2001, 47(2-3):281-292.
20. Mark T.L., Dirani R., Slade E., Russo P.A. Access to new medications to treat schizophrenia. J Behav Health Serv Res 2002, 29(1):15-29.
21. Fountoulakis K.N., Nimatoudis I., Iacovides A., Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004, 3(1):4.
22. Jano E., Chen H., Johnson M.L., Aparasu R.R. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv 2007, 58(11):1400.
23. Huskamp H.A. Pharmaceutical cost management and access to psychotropic drugs: the U.S. context. Int J Law Psychiatry 2005, 28(5):484-495.
24. Aparasu R.R., Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006, 57(12):1693.
25. Copeland L.A., Zeber J.E., Valenstein M., Blow F.C. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 2003, 160(10):1817-1822.
26. Domino M.E., Swartz M.S. Who are the new users of antipsychotic medications?. Psychiatr Serv 2008, 59(5):507-514.
27. Han E., Liu G.G. Racial disparities in prescription drug use for mental illness among population in US. J Ment Health Policy Econ 2005, 8(3):131-143.
28. Herbeck D.M., West J.C., Ruditis I., et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 2004, 55(6):677-684.
29. Jano E., Johnson M., Chen H., Aparasu R.R. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin 2008, 24(3):709-716. Epub 2008 Jan 25.
30. Kuo T.C., Zhao Y., Weir S., Kramer M.S., Ash A.S. Implications of comorbidity on costs for patients with Alzheimer disease. Med Care 2008, 46(8):839-846.
31. Luo R.D., Belleti D.A., Tran D., Arcona S., Salen P.N. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia. Int J Psychiatry Med 2002, 32(3):261-269.
32. Mallinger J.B., Fisher S.G., Brown T., Lamberti J.S. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006, 57(1):133-136.
33. Opolka J.L., Rascati K.L., Brown C.M., Gibson P.J. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 2004, 55(2):151-156.
34. Rothbard A.B., Kuno E., Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003, 29(3):531-540.
35. Van Brunt D.L., Gibson P.J., Ramsey J.L., Obenchain R. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. MedGenMed 2003, 5(3):16.
36. Wysowski D.K., Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry 1989, 46(10):929-932.
37. Woods S.W., Sullivan M.C., Neuse E.C., et al. Best practices: racial and ethnic effects on antipsychotic prescribing practices in a community mental health center. Psychiatr Serv 2003, 54(2):177-179.
38. Andersen R.M. Revisiting the behavioral model and access to medical care: does it matter?. J Health Soc Behav 1995, 36(1):1-10.
39. Andersen R.M. National health surveys and the behavioral model of health services use. Med Care 2008, 46(7):647-653.
40. Agency for Healthcare Research and Quality MEPS HC-036: 1996-2005 Pooled Estimation File 2007, Agency for Healthcare Research and Quality, Rockville, MD.
41. Jeste D.V., Alexopoulos G.S., Bartels S.J., et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry 1999, 56(9):848-853.
42. Osborn D.P. The poor physical health of people with mental illness. West J Med 2001, 175(5):329-332.
43. Mojtabai R. Unmet need for treatment of major depression in the United States. Psychiatr Serv 2009, 60(3):297-305.
44. Wang P.S., Demler O., Olfson M., Pincus H.A., Wells K.B., Kessler R.C. Changing profiles of service sectors used for mental health care in the United States. Am J Psychiatry 2006, 163(7):1187-1198.
45. Soumerai S.B., McLaughlin T.J., Ross-Degnan D., Casteris C.S., Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994, 331(10):650-655.
46. Findling R.L., McNamara N.K. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004, 65(Suppl 6):30-44.
47. Patel N.C., Crismon M.L., Hoagwood K., et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005, 44(6):548-556.
48. Zhu B., Kulkarni P.M., Stensland M.D., Ascher-Svanum H. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Curr Med Res Opin 2007, 23(11):2805-2814.
49. Kuno E., Rothbard A.B. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002, 159(4):567-572.
50. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223. Epub 2005 Sep 19.
51. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63(10):1079-1087.